The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- JCR Aims at Growth through New Products, Out-Licensing Activities
July 2, 2015
- Merck Serono, Nippon Shinyaku to Copromote Gonalef
July 2, 2015
- Announcement: 2nd Annual Oncology Asia - Sheraton Miyako Hotel Tokyo, September 7-9
July 2, 2015
- Bayer Files for Regulatory Approval of Hemophilia A Treatment in Japan
July 1, 2015
- Daiichi Sankyo Acquires Additional Shares in Kitasato Daiichi Sankyo Vaccine for 10 Billion Yen
July 1, 2015
- Febuxostat Approved for Hyperuricemia Associated with Cancer Chemotherapy in Europe: Teijin Pharma
July 1, 2015
- Taisho, Ablynx of Belgium to Collaborate for Development and Commercialization of Anti-TNF-α Nanobody
July 1, 2015
- Otsuka Initiates Voluntary Recall of Uniphyl
June 30, 2015
- Takecab Slips to 2nd Place as Suglat Comes 1st in GP Market in May: Anterio Ranking
June 30, 2015
- Bayer Obtains Approval for Eylea for Macular Edema Secondary to Retinal Vein Occlusion
June 30, 2015
- Study for Myelodysplastic Syndrome in Japan: SymBio
June 30, 2015
- Takeda Chairman Hasegawa Gives Up Representative Rights
June 29, 2015
- Aspen Japan Takes Over Decadron from MSD
June 29, 2015
- UCB Japan Applies for Approval of Antiepileptic Agent Lacosamide in Japan
June 29, 2015
- RaQualia Regains Domestic Rights to Dalbavancin from Allergan
June 29, 2015
- Lixiana Gets EU Regulatory Approval: Daiichi Sankyo
June 26, 2015
- EU OKs Fycompa as Adjunct Therapy for PGTC Seizures: Eisai
June 26, 2015
- Sosei Group “Not in Hurry” to License Out Compounds Obtained through Heptares Acquisition: President Tamura
June 26, 2015
- Naldemedine Meets Primary, Secondary Endpoints in Japanese PIII Study for the Treatment of OIC in Cancer Patients: Shionogi
June 26, 2015
- Novartis Seeks Japan Approval of Ceritinib
June 25, 2015
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…